TriSalus Life Sciences (TLSI) Expected to Post Quarterly Earnings on Tuesday

TriSalus Life Sciences (NASDAQ:TLSI) will likely be announcing its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect TriSalus Life Sciences to post earnings of ($0.14) per share and revenue of $14.02 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:30 AM ET.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). The business had revenue of $11.41 million during the quarter, compared to analyst estimates of $10.27 million. On average, analysts expect TriSalus Life Sciences to post ($0.53) EPS for the current fiscal year and ($0.28) EPS for the next fiscal year.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI opened at $3.25 on Monday. TriSalus Life Sciences has a 12 month low of $2.20 and a 12 month high of $7.95. The company’s 50-day moving average price is $4.28 and its two-hundred day moving average price is $4.36. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05. The firm has a market cap of $200.13 million, a P/E ratio of -2.50 and a beta of 0.50.

Analyst Ratings Changes

A number of research firms have recently weighed in on TLSI. Zacks Research upgraded TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Wednesday. Guggenheim set a $12.00 price objective on TriSalus Life Sciences in a report on Wednesday, September 23rd. HC Wainwright increased their target price on TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, September 23rd. Finally, Stifel Nicolaus set a $12.00 target price on TriSalus Life Sciences in a research note on Wednesday, September 23rd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.20.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.